Piramal Pharma Limited — Others, 28-01-2025: Appointment

Piramal Pharma Limited has announced a board meeting where it approved the unaudited financial results for the quarter and nine months ended December 31, 2024. The company reported revenue from operations of ₹1,248.32 Cr for Q3 FY2025, a notable increase from ₹1,024.14 Cr in the corresponding period last year. Profit after tax stood at ₹118.80 Cr compared to ₹74.34 Cr a year ago, reflecting improving financial health. Additionally, Ms. Nathalie Leitch has been appointed as an Additional Director, which could enhance strategic oversight in a competitive market. Overall, this development presents a positive outlook for investors looking for growth in the pharmaceuticals sector.